The core activity of LASCCO SA is the development and marketing of diagnostic tests, in particular the Pancreatic Stone Protein (PSP) test, which is used for the early detection of sepsis. The PSP test is a diagnostic tool that enables the identification of patients at high risk of sepsis, thereby reducing the time to detection and treatment of sepsis.
AI-generated
Offering
Products & services
Industry:Licensing & Marketing of Intellectual Property
✓ Offered1
Licensing of PSP Diagnostics
Licensing of the Pancreatic Stone Protein (PSP) sepsis test, commercial rights to partners, use as diagnostics for early sepsis detection and triage.
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.